HIV-associated neurocognitive disorder is associated with HIV-1 dual infection
- PMID: 27536983
- PMCID: PMC5083206
- DOI: 10.1097/QAD.0000000000001237
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection
Abstract
Objective: Compared with HIV monoinfection, HIV dual infection has been associated with decreased CD4 T-cell counts and increased viral loads. The same markers are also associated with the development of HIV-associated neurocognitive disorder (HAND), which continues to be a prevalent problem in the era of combination antiretroviral therapy (ART). We sought to determine the relationship between dual infection and HAND.
Methods: Participants on ART (N = 38) underwent deep sequencing of four PCR-amplified HIV coding regions derived from peripheral blood mononuclear cell DNA samples. Phylogenetic analyses were performed to evaluate whether two distinct viral lineages, that is, dual infection, were present in the same individual. All study participants underwent neurocognitive, substance use, and neuromedical assessments at each study visit.
Results: Of 38 participants, nine (23.7%) had evidence of dual infection. Using clinical ratings, global neurocognitive impairment was identified in 21 (55%) participants, and multivariate analysis demonstrated a significant association between dual infection and impairment; odds ratio (95% confidence interval) = 18.3 (1.9, 414.2), P = 0.028. Neurocognitive impairment was also associated with lower current (P = 0.028) and nadir (P = 0.043) CD4 T-cell counts.
Conclusions: Deep sequencing of HIV DNA populations in blood mononuclear cell identified dual infection in nearly a quarter of HIV-infected adults receiving ART, and dual infection was associated with HAND. Dual infection may contribute to the development of HAND, perhaps because of increased viral diversity. Further investigation is needed to determine how dual infection results in worse neurocognitive performance.
Figures

References
-
- Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis. 2005;192:438–444. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN271201000030C/MH/NIMH NIH HHS/United States
- R01 AI047745/AI/NIAID NIH HHS/United States
- HHSN271201000036C/MH/NIMH NIH HHS/United States
- R21 AI047745/AI/NIAID NIH HHS/United States
- KL2 TR001444/TR/NCATS NIH HHS/United States
- T32 AI007384/AI/NIAID NIH HHS/United States
- R56 AI047745/AI/NIAID NIH HHS/United States
- P30 MH062512/MH/NIMH NIH HHS/United States
- P30 AI036214/AI/NIAID NIH HHS/United States
- N01 MH022005/MH/NIMH NIH HHS/United States
- R01 MH097520/MH/NIMH NIH HHS/United States
- K24 AI100665/AI/NIAID NIH HHS/United States
- K24 MH097673/MH/NIMH NIH HHS/United States
- R01 MH107345/MH/NIMH NIH HHS/United States
- U19 AI096113/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials